CN108553466A - 一种用于真菌性皮肤病的外用组合物 - Google Patents
一种用于真菌性皮肤病的外用组合物 Download PDFInfo
- Publication number
- CN108553466A CN108553466A CN201810355789.0A CN201810355789A CN108553466A CN 108553466 A CN108553466 A CN 108553466A CN 201810355789 A CN201810355789 A CN 201810355789A CN 108553466 A CN108553466 A CN 108553466A
- Authority
- CN
- China
- Prior art keywords
- ketoconazole
- composition
- topical composition
- compound
- fungal dermatopathy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 29
- 230000002538 fungal effect Effects 0.000 title claims abstract description 19
- 230000000699 topical effect Effects 0.000 title claims abstract description 15
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 claims abstract description 40
- 229960004125 ketoconazole Drugs 0.000 claims abstract description 39
- 150000001875 compounds Chemical class 0.000 claims abstract description 28
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 19
- 238000002360 preparation method Methods 0.000 claims abstract description 12
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims abstract description 10
- 229920002125 Sokalan® Polymers 0.000 claims abstract description 10
- 229960001631 carbomer Drugs 0.000 claims abstract description 10
- 239000000470 constituent Substances 0.000 claims abstract description 7
- 239000000463 material Substances 0.000 claims abstract description 7
- WQVOUANKVCYEIQ-UHFFFAOYSA-N 1,3-thiazol-4-ylmethanol Chemical compound OCC1=CSC=N1 WQVOUANKVCYEIQ-UHFFFAOYSA-N 0.000 claims abstract description 5
- 239000004909 Moisturizer Substances 0.000 claims abstract description 5
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims abstract description 5
- 230000001333 moisturizer Effects 0.000 claims abstract description 5
- 239000003755 preservative agent Substances 0.000 claims abstract description 5
- 230000002335 preservative effect Effects 0.000 claims abstract description 5
- 239000002904 solvent Substances 0.000 claims abstract description 5
- 239000004094 surface-active agent Substances 0.000 claims abstract description 5
- 229920002554 vinyl polymer Polymers 0.000 claims abstract description 5
- 239000003002 pH adjusting agent Substances 0.000 claims abstract description 3
- 239000003349 gelling agent Substances 0.000 claims abstract 2
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims description 33
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 14
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 12
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 7
- 229920000053 polysorbate 80 Polymers 0.000 claims description 7
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 6
- 235000011187 glycerol Nutrition 0.000 claims description 6
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 claims description 4
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 claims description 4
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 claims description 4
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical group CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 claims description 4
- WLAMNBDJUVNPJU-UHFFFAOYSA-N 2-methylbutyric acid Chemical group CCC(C)C(O)=O WLAMNBDJUVNPJU-UHFFFAOYSA-N 0.000 claims description 3
- 229940082484 carbomer-934 Drugs 0.000 claims description 3
- JVTIXNMXDLQEJE-UHFFFAOYSA-N 2-decanoyloxypropyl decanoate 2-octanoyloxypropyl octanoate Chemical compound C(CCCCCCC)(=O)OCC(C)OC(CCCCCCC)=O.C(=O)(CCCCCCCCC)OCC(C)OC(=O)CCCCCCCCC JVTIXNMXDLQEJE-UHFFFAOYSA-N 0.000 claims description 2
- 150000003851 azoles Chemical class 0.000 claims 1
- 150000002576 ketones Chemical class 0.000 claims 1
- 150000003936 benzamides Chemical class 0.000 abstract 3
- 229940054066 benzamide antipsychotics Drugs 0.000 abstract 1
- 125000005936 piperidyl group Chemical group 0.000 abstract 1
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 24
- 241000894006 Bacteria Species 0.000 description 16
- 239000003814 drug Substances 0.000 description 12
- 230000000694 effects Effects 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 241000233866 Fungi Species 0.000 description 8
- 239000012153 distilled water Substances 0.000 description 8
- 238000003756 stirring Methods 0.000 description 8
- 229940079593 drug Drugs 0.000 description 7
- 241000222122 Candida albicans Species 0.000 description 6
- 229940095731 candida albicans Drugs 0.000 description 6
- 235000019441 ethanol Nutrition 0.000 description 6
- 239000001965 potato dextrose agar Substances 0.000 description 6
- 210000003491 skin Anatomy 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 239000001963 growth medium Substances 0.000 description 5
- 208000001840 Dandruff Diseases 0.000 description 4
- 230000001408 fungistatic effect Effects 0.000 description 4
- 230000003902 lesion Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 229920000136 polysorbate Polymers 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 241000223229 Trichophyton rubrum Species 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 230000001857 anti-mycotic effect Effects 0.000 description 3
- 239000002543 antimycotic Substances 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000013316 zoning Methods 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 2
- 241001480043 Arthrodermataceae Species 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000000843 anti-fungal effect Effects 0.000 description 2
- 229940121375 antifungal agent Drugs 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 230000037304 dermatophytes Effects 0.000 description 2
- 239000003292 glue Substances 0.000 description 2
- 231100000753 hepatic injury Toxicity 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 230000037311 normal skin Effects 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 238000007747 plating Methods 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- AMNAZJFEONUVTD-KEWDHRJRSA-N (2s,3s,4s,5r,6r)-6-(4-amino-2-oxopyrimidin-1-yl)-4,5-dihydroxy-3-[[(2s)-3-hydroxy-2-[[2-(methylamino)acetyl]amino]propanoyl]amino]oxane-2-carboxamide Chemical compound O1[C@H](C(N)=O)[C@@H](NC(=O)[C@H](CO)NC(=O)CNC)[C@H](O)[C@@H](O)[C@@H]1N1C(=O)N=C(N)C=C1 AMNAZJFEONUVTD-KEWDHRJRSA-N 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- UQBOJOOOTLPNST-UHFFFAOYSA-N Dehydroalanine Chemical class NC(=C)C(O)=O UQBOJOOOTLPNST-UHFFFAOYSA-N 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- FEACDOXQOYCHKU-UHFFFAOYSA-N Gougerotin Natural products CNCC(=O)NC1=NC(=O)N(C=C1)C2OC(C(O)C(NC(=O)C(N)CO)C2O)C(=O)N FEACDOXQOYCHKU-UHFFFAOYSA-N 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 244000137852 Petrea volubilis Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 241000222126 [Candida] glabrata Species 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000000629 anti-dermatophyte Effects 0.000 description 1
- 239000012871 anti-fungal composition Substances 0.000 description 1
- 238000004500 asepsis Methods 0.000 description 1
- 208000032343 candida glabrata infection Diseases 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000000280 densification Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000002951 depilatory effect Effects 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 210000003746 feather Anatomy 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229940084434 fungoid Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229910052602 gypsum Inorganic materials 0.000 description 1
- 239000010440 gypsum Substances 0.000 description 1
- 150000002460 imidazoles Chemical class 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 238000010422 painting Methods 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229940126532 prescription medicine Drugs 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000004080 punching Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
一种用于真菌性皮肤病的外用组合物,由作为活性成分的酮康唑和(Z)‑N‑[1‑[[[4‑[2‑(4‑羟甲基噻唑)]]‑1‑哌啶基]羰基]‑2‑苯基乙烯基]苯甲酰胺(31),和至少一种适用于皮肤外用的辅料组成;所述组合物中酮康唑的含量为质量百分比含量为0.4%~0.5%,化合物(31)与酮康唑的质量比为1:0.7~1.3。所述组合物制成凝胶剂。所述辅料选自卡波姆、保湿剂、溶剂、防腐剂、表面活性剂、pH调节剂中的一种或几种,以及余量的水。
Description
技术领域:
本发明提供了一种外用抗真菌组合物。
背景技术:
真菌性皮肤病指由病原真菌所引起的人类皮肤以及黏膜、毛发和甲等皮肤附属器的一大类感染性疾病。是皮肤癣菌侵犯表皮,所引起的浅部真菌感染性疾病。真菌性皮肤病的病原真菌有包括红色毛癣菌、白色念珠菌在内的多种。在临床上治疗真菌性皮肤病多采用外用抗真菌药物。在治疗真菌性皮肤中多采用外用抗真菌药物和自己,酮康唑(ketoconazole,CAS:65277-42-1)是一种咪唑类广谱抗真菌药,广泛的用于各种真菌性皮肤病的治疗,但是由于容易造成严重的肝损伤,酮康唑口服制剂已经遭到停产处理,且现有的多种含有酮康唑的外用药也被重新确定为处方药。由于具有造成严重副作用的危险性,酮康唑的使用受到了很大的限制。现有的酮康唑外用制剂酮康唑含量一般为2%。如何在现有技术基础上,合理组成复方以提供一种用于治疗真菌性皮肤病的外用组合物,能够提高酮康唑制剂的效果,并通过降低外用制剂中酮康唑用量来避免其造成肝损伤的潜在副作用成为现有技术中亟待解决的问题。
发明内容:
在研究中我们发现中国专利文献CN 107216282A公开了一系列可以用于植物杀菌剂的α-氨基丙烯酸类衍生物,并具体公开了化合物(Z)-N-[1-[[[4-[2-(4-羟甲基噻唑)]]-1-哌啶基]羰基]-2-苯基乙烯基]苯甲酰胺(31),该文献中指出化合物(31)对一些植物病原体具有有一定防治效果,但其效果明显低于作为对照药物的宁南霉素。在研究中我们惊奇的发现,化合物(31)与酮康唑联合用药,能显著提高真菌性皮肤病常见病原的抑菌效果。基于上述发现,本发明提供的技术方案为:
一种用于真菌性皮肤病的外用组合物,其特征在于所述组合物由作为活性成分的酮康唑和(Z)-N-[1-[[[4-[2-(4-羟甲基噻唑)]]-1-哌啶基]羰基]-2-苯基乙烯基]苯甲酰胺(31),和至少一种适用于皮肤外用的辅料组成;所述组合物中酮康唑的含量为质量百分比含量为0.4%~0.5%,化合物(31)与酮康唑的质量比为1:0.7~1.3。
一种用于真菌性皮肤病的外用组合物,其特征在于所述化合物(31)与酮康唑的质量比为1:0.9~1.1。
所述的一种用于真菌性皮肤病的外用组合物,其特征在于所述组合物制成凝胶剂。所述辅料选自卡波姆、保湿剂、溶剂、防腐剂、表面活性剂、pH调节剂中的一种或几种,以及余量的水。
所述卡波姆选自卡波姆934,卡波姆940,卡波姆941中的一种,所述卡波姆用量为组合物总质量的0.5%~1.5%。所述溶剂优选乙醇。所述的保湿剂优选丙三醇或丙二醇。用量为4%~8%。所述表面活性剂优选吐温-80,用量为0.5%~1%。所述防腐剂为尼泊金乙酯。
本发明中所述百分比均为占组合物的重量百分比。
在体外抑菌效果研究中,我们意外的发现,当化合物(31)与酮康唑的配比确定为1:1时可以显著提高对红色毛癣菌等多种真菌性皮肤病病原的抑菌效果,基于此发现我们提供了一种用于真菌性皮肤病的外用组合物,并将组合物中的化合物(31)与酮康唑的配比确定为1:07~1.3,与单独使用酮康唑或化合物(31)相比,本发明提供的外用组合物对常见的人体皮肤真菌病的病原可以产生更好的治疗效果。说明特定比例的化合物(31)与酮康唑产生了协同的抗真菌皮肤感染效果,在酮康唑含量仅为0.4%~0.5%的情况下能够表现出较好的治疗效果,避免了现有制剂中酮康唑用量较高而带来的潜在风险。在进一步实验中我们发现,化合物(31)与酮康唑的配比在1:0.9~1.1时,上述协同效果更为明显,且化合物(31)与在现有的多种抗真菌药物中,仅与酮康唑联用能够表现出明显的协同效应。
具体实施方式:
化合物(31)的制备,按照中国专利文献CN107216282A中公开的方法,制备(Z)-N-[1-[[[4-[2-(4-羟甲基噻唑)]]-1-哌啶基]羰基]-2-苯基乙烯基]苯甲酰胺(31)原料药,含量98%以上。
药理实施例1、体外抑菌效果实验
1、培养基的制备
马铃薯葡萄糖琼脂培养基(PDA),质量分数为马铃薯20%、葡萄糖2%、琼脂1.8%。每个试管中加入5ml培养基制备成斜面培养基;直径90mm的平皿中加入20ml培养基制备成平板培养基
2、实验方法
2.1菌株的处理
①将阳性菌落使用灭菌接种环转种于平皿PDA培养基活化菌株,丝状型真菌采取一区划线法,置于28℃恒温培养箱,培养7天;念珠菌使用三区划线法,置于35℃恒温培养箱,培养2天。
②挑取无污染的菌落采取三区划线法转种于平皿PDA培养基进行分纯,培养条件同前。
③挑取单独的纯化菌落以“Z”字形转种于斜面SDA试管培养基中,丝状型真菌置于28℃恒温培养箱,培养10天后经玻片小培养鉴定到种;念珠菌置于35℃恒温箱,培养2天后接种于科玛嘉培养基显色鉴定到种。
本实验采用的的菌株分别为属于皮肤癣菌的红色毛癣菌、须癣毛癣菌、石膏小孢子菌和属于念珠菌的白色念珠菌和光滑念珠菌
2.2制作菌悬液
挑取适当菌落团块,溶于1mL加入吐温80的0.9%灭菌生理盐水。用微量振荡器震荡2min,充分震荡洗脱出孢子,使用血细胞计数器调节菌悬液浊度至5×106~10×106CFU/mL。
2.3制作含菌平板
抽取0.5ml菌悬液置于PDA平皿培养基,用灭菌涂布棒使之均匀分布于培养基表面。
2.4打孔加药
以直径6mm的打孔器在涂菌后的培养基上打孔,挑去孔内琼脂,将待测试药物分别挤入1ml无菌注射器中,每孔内加药0.1ml。
将活性成分溶于DMSO后再按下表所示浓度配制成混合溶液后,作为各组的待测试药物
实验组号 | 1 | 2 | 3 | 4 | 5 | 6 | 7 |
化合物(31)% | 0.3 | 0.4 | 0.5 | 0.6 | 0.7 | 1 | 0 |
酮康唑% | 0.7 | 0.6 | 0.5 | 0.4 | 0.3 | 0 | 1 |
2.5培养与结果测量
药敏实验平板置于28℃恒温培养箱,培养10天。使用游标卡尺测量每种药的抑菌环半径,记录各药孔周围抑菌圈半径mm值。每株菌同时做3个平板。
结果如下(单位mm,n=3,means±s)
体外抑菌实验的结果表明,与单用活性成分的实验组6/7和采用其他比例的各实验组相比,实验组3对各种致病真菌的抑制效果显著提高,尤其是对于白色念珠菌,其抑菌效果的提高程度更为明显。基于上述实验结果,以接近1:1的比例确定化合物(31)与酮康唑的比例为1:0.7~1.3,并基于该比例制备制剂实施例的外用组合物。
。实施例1
化合物(31)5.2g酮康唑4g、,
卡波姆940 5g,丙三醇50g吐温80 5g
尼泊金乙酯1g氢氧化钠4g蒸馏水加至1000g
将卡波姆与吐温80及300ml蒸馏水混合,氢氧化钠溶于100ml水后加入上液搅匀,再将酮康唑及化合物(31)溶于适量乙醇后逐渐加入搅匀,补足余量的水搅匀即得透明凝胶。
实施例2
化合物(31)3.5g酮康唑5g
卡波姆934 10g丙三醇50g吐温80 5g
氢氧化钠4g蒸馏水加至1000g
将卡波姆与吐温80及300ml蒸馏水混合,氢氧化钠溶于100ml水后加入上液搅匀,再将酮康唑及化合物(31)溶于适量乙醇后逐渐加入搅匀,补足余量的水搅匀即得透明凝胶。
实施例3
化合物(31)4.4g、酮康唑4g
卡波姆940 15g丙三醇50g吐温80 5g
尼泊金乙酯1g氢氧化钠4g蒸馏水加至1000g
将卡波姆与吐温80及300ml蒸馏水混合,氢氧化钠溶于100ml水后加入上液搅匀,再将酮康唑及化合物(31)溶于乙醇后逐渐加入搅匀,补足余量的水搅匀即得透明凝胶。
实施例4
化合物(31)4.5g、酮康唑5g
卡波姆940 10g乙醇60g丙三醇80g吐温80 10g
尼泊金乙酯1g氢氧化钠4g蒸馏水加至1000g
将卡波姆与吐温80及300ml蒸馏水混合,氢氧化钠溶于100ml水后加入上液搅匀,再将酮康唑及化合物(31)溶于乙醇后逐渐加入搅匀,补足余量的水搅匀即得透明凝胶。
对比例1
按照实施例1的配方,将活性成分改为酮康唑10g。
对比例2
按照实施例1的配方,将活性成分改为化合物(31)10g。
药理实施例1真菌抑菌效果对比实验
1、材料
实验动物为Hartley豚鼠,体重300±20g,雌雄各半,
2、菌悬液的制备
将须癣毛癣菌菌株在PDA固体培养基上连续传代培养2次(28℃),以保证其活力。于第二次培养5d后,挑其菌落与0.9%生理盐水中,制成终浓度为1×108CFU/mL的菌悬液。
3、造模
豚鼠背部剃刀剃毛,用日本脱毛蜡脱毛,形成沿脊柱对称的两个4.0cm×4.0cm的无毛区。对无毛区进行真菌直接镜检及培养,结果均为阴性确认为阴性后用砂纸在豚鼠背上轻轻均匀地摩擦,并将菌悬液200μL均匀涂布于背部无毛区。涂菌1次后,连续观察10天。
4、分组及给药
取造模成功的实验动物随机分组,每组5只,每只动物的两个无毛区,给予同一种药物,连续给药7d,并记录给药前和给药7d后的评分,
评分标准
4分:红、肿、皮肤增厚,皮屑致密布满整个皮损部位。
3分:红、肿,皮损部位皮屑间有点状正常皮肤,累计小于25%。
2分:微红、不肿,皮损部位皮屑间有线状正常皮肤,累计小于50%。
1分:不红、不肿,皮损部位有少许皮屑间,75%以上皮肤正常。
0分:不红、不肿,基本正常。
分组给药与实验结果见下表
实验结果表明,实验1~4组采用本发明实施例提供的组合物,其对真菌感染模型动物的治疗效果既优于对照组,也优于采用单一活性成分的实验5/6组,说明本发明提供的组合物通过优选两种活性成分的比例,提高了对于皮肤真菌感染的治疗效果,特别是实验3/4组,在酮康唑用量仅为0.4%~0.5%的情况下,其效果也明显优于其他实施例,说明特别优选的化合物(31)与酮康唑比例(1:0.9~1.1)能够表现出更好的抗皮肤真菌感染效果。
Claims (5)
1.一种用于真菌性皮肤病的外用组合物,其特征在于所述组合物由作为活性成分的酮康唑和(Z)-N-[1-[[[4-[2-(4-羟甲基噻唑)]]-1-哌啶基]羰基]-2-苯基乙烯基]苯甲酰胺(31),和至少一种适用于皮肤外用的辅料组成;所述组合物中酮康唑的含量为质量百分比含量为0.4%~0.5%,化合物(31)与酮康唑的质量比为1:0.7~1.3。
2.如权利要求1所述的一种用于真菌性皮肤病的外用组合物,其特征在于所述化合物(31)与酮康唑的质量比为1:0.9~1.1。
3.如权利要求1或2所述的一种用于真菌性皮肤病的外用组合物,其特征在于所述组合物制成凝胶剂。
4.如权利要求3所述的一种用于真菌性皮肤病的外用组合物,其特征在于所述辅料选自卡波姆、保湿剂、溶剂、防腐剂、表面活性剂、pH调节剂中的一种或几种,以及余量的水。
5.如权利要求4所述的一种用于真菌性皮肤病的外用组合物,其特征在于如所述卡波姆选自卡波姆934,卡波姆940,卡波姆941中的一种,所述卡波姆用量为组合物总质量的0.5%~1.5%;所述溶剂优选乙醇;所述的保湿剂优选丙三醇或丙二醇,用量为4%~8%;所述表面活性剂优选吐温-80,用量为0.5%~1%;所述防腐剂为尼泊金乙酯。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810355789.0A CN108553466A (zh) | 2018-04-19 | 2018-04-19 | 一种用于真菌性皮肤病的外用组合物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810355789.0A CN108553466A (zh) | 2018-04-19 | 2018-04-19 | 一种用于真菌性皮肤病的外用组合物 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN108553466A true CN108553466A (zh) | 2018-09-21 |
Family
ID=63535981
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810355789.0A Pending CN108553466A (zh) | 2018-04-19 | 2018-04-19 | 一种用于真菌性皮肤病的外用组合物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN108553466A (zh) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1899291A (zh) * | 2006-07-24 | 2007-01-24 | 昆明滇虹药业有限公司 | 外用抗真菌的复方组合物及其应用 |
CN102218052A (zh) * | 2011-04-08 | 2011-10-19 | 中国人民解放军第二军医大学 | 山奈酚作为抗真菌药物增效剂的用途 |
CN103536613A (zh) * | 2013-10-14 | 2014-01-29 | 中国科学院微生物研究所 | 一种抗真菌的药物组合物 |
WO2014041424A1 (en) * | 2012-09-14 | 2014-03-20 | Methylgene Inc. | Histone deacetylase inhibitors for enhancing activity of antifungal agents |
CN107216282A (zh) * | 2017-05-16 | 2017-09-29 | 南开大学 | 一种α‑氨基丙烯酸类杀微生物剂及其制备方法和用途 |
-
2018
- 2018-04-19 CN CN201810355789.0A patent/CN108553466A/zh active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1899291A (zh) * | 2006-07-24 | 2007-01-24 | 昆明滇虹药业有限公司 | 外用抗真菌的复方组合物及其应用 |
CN102218052A (zh) * | 2011-04-08 | 2011-10-19 | 中国人民解放军第二军医大学 | 山奈酚作为抗真菌药物增效剂的用途 |
WO2014041424A1 (en) * | 2012-09-14 | 2014-03-20 | Methylgene Inc. | Histone deacetylase inhibitors for enhancing activity of antifungal agents |
CN103536613A (zh) * | 2013-10-14 | 2014-01-29 | 中国科学院微生物研究所 | 一种抗真菌的药物组合物 |
CN107216282A (zh) * | 2017-05-16 | 2017-09-29 | 南开大学 | 一种α‑氨基丙烯酸类杀微生物剂及其制备方法和用途 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102470117B (zh) | 一种以苯甲酸和有机酸防腐剂相联合作为有效成分的组合物及其用途 | |
JP4414623B2 (ja) | 病原微生物および抗微生物剤の検出法、抗微生物剤の薬効評価法ならびに抗微生物剤 | |
CN104688648B (zh) | 一种口腔用组合物及其制备方法 | |
Sánchez et al. | Use of propolis for topical treatment of dermatophytosis in dog | |
CN108042578A (zh) | 一种含有复合益生菌成分的保健阴道凝胶 | |
JP2005200339A (ja) | 抗菌剤 | |
Ling et al. | Preparation, characterization, and pharmacokinetics of tilmicosin‐and florfenicol‐loaded hydrogenated castor oil‐solid lipid nanoparticles | |
CN105998171B (zh) | 秦艽及其提取物在制备治疗和/或预防皮肤癣的药物的用途 | |
Arika et al. | Effects of butenafine hydrochloride, a new benzylamine derivative, on experimental tinea pedis in guinea pigs | |
CN101543658A (zh) | 防治宫颈糜烂的宫颈帽及其制备方法 | |
RU2537143C1 (ru) | Препарат для лечения и профилактики мастита у коров | |
CN113384570A (zh) | 咖啡酸甲酯及与三唑类组合物在制备抗真菌产品中的应用 | |
CN108553466A (zh) | 一种用于真菌性皮肤病的外用组合物 | |
CN108420821A (zh) | 一种复方抗真菌外用组合物 | |
CN108606967A (zh) | 一种复方酮康唑外用组合物 | |
CN102743432B (zh) | 藿香油在制备治疗阴道炎的药物中的用途 | |
CN104667267A (zh) | 一种皮肤外用溶菌酶复合制剂及制造方法 | |
CN108272749A (zh) | 一种用于抗真菌的复方外用组合物 | |
CN108653247A (zh) | 一种具备吸收退热功效的退热贴的制备方法 | |
CN108309979A (zh) | 一种复方外用抗真菌剂 | |
CN110193017B (zh) | 一种促毛发生长的喷膜剂及其制备方法 | |
CN108606966A (zh) | 一种抗真菌外用组合物 | |
CN108434143A (zh) | 一种基于蜂斗菜提取物的复方外用抗真菌组合物 | |
CN108553465A (zh) | 一种用于真菌感染的复方酮康唑外用组合物 | |
CN108853103A (zh) | 含有一种蜂斗菜内酯的抗真菌皮肤用组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20180921 |
|
WD01 | Invention patent application deemed withdrawn after publication |